Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Keros Therapeutics (KROS) Preferred Shares Issued (2020)

Keros Therapeutics (KROS) has disclosed Preferred Shares Issued for 1 consecutive years, with $56.0 million as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Preferred Shares Issued changed N/A year-over-year to $56.0 million, compared with a TTM value of $56.0 million through Dec 2020, changed N/A, and an annual FY2020 reading of $56.0 million, changed N/A over the prior year.
  • Preferred Shares Issued was $56.0 million for Q1 2020 at Keros Therapeutics.
  • Across five years, Preferred Shares Issued topped out at $56.0 million in Q1 2020 and bottomed at $56.0 million in Q1 2020.